Literature DB >> 17848143

Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors.

Svjetlana Radović1, Mirsad Babić, Mirsad Dorić, Ajna Hukić, Suada Kuskunović, Ademir Hadzismajlović, Fadila Serdarević.   

Abstract

The aim of this study was to investigate expression of cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins in 14 cases of non-small cell lung cancer and to establish their correlation to classical clinico-pathological findings, and alleged prognostic value to estimate biological potential of tumor. Retrospective pilot study of the surgically treated non-small cell lung cancer biopsy specimen, paraffin embedded, used immunohistochemical method to demonstrate expression of cyclin D1, bcl-2, p53, Ki-67 and HER-2. Protein quantification was performed by the semi-quantitative method. Achieved results were correlated with classical clinico-pathological parameters, like tumor size, histological type, differentiation level, presence of vascular invasion and metastasis in regional lymph nodes. Out of 14 cases of non-small cell lung cancer, squamous cell carcinoma was found in 7 patients, giant cell carcinoma in 3, adenocarcinoma in 2, and 1 case of pleomorphic and mucoepidermoid carcinoma. Expression of cyclin D1 was not found, while expression of HER-2 and bcl-2 protein was established in one cases each. p53 expression was noted in 8 cases (57,1%). Statistically positive significant correlation (p<0,05) was found among: presence of lymphovascular invasion to tumor tissue and appearance of nodal metastasis; proliferation Ki-67 index and level of tumor differentiation, i.e. size of tumor. Other investigated parameters showed no significant statistically dependence. p53 expression was not correlated to any of the investigated parameters what might imply the possibility that there is an independent pathway of this protein expression. Negative expression of bcl-2 protein points out to possibility that it is not included into process of tumor apoptosis, as well as that proteins cyclin D1 and HER-2 are not included into processes of the tumor genesis. Since the proliferative activity of the tumor, measured by the expression of Ki-67, is correlated to the gradus and size of the tumor mass, Ki-67 protein can be of a prognostic value to determine biological potential of non-small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17848143      PMCID: PMC5736109          DOI: 10.17305/bjbms.2007.3045

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  40 in total

1.  [Proliferation kinetics of bronchioloalveolar tumorlets].

Authors:  A Theile; K M Müller
Journal:  Pathologe       Date:  1996-03       Impact factor: 1.011

2.  Investigation of HER2 overexpression in non-small cell lung cancer.

Authors:  Katalin Ugocsai; László Mándoky; László Tiszlavicz; Joseph Molnár
Journal:  Anticancer Res       Date:  2005 Jul-Aug       Impact factor: 2.480

3.  Amplification at chromosome 11q13 in transitional cell tumours of the bladder.

Authors:  A J Proctor; L M Coombs; J P Cairns; M A Knowles
Journal:  Oncogene       Date:  1991-05       Impact factor: 9.867

Review 4.  HER2 as a prognostic factor in breast cancer.

Authors:  S Ménard; S Fortis; F Castiglioni; R Agresti; A Balsari
Journal:  Oncology       Date:  2001       Impact factor: 2.935

5.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

6.  Frequent amplification of the bcl-1 locus in poorly differentiated squamous cell carcinoma of the lung. The Lung Cancer Study Group.

Authors:  J R Berenson; H Koga; J Yang; J Pearl; E C Holmes; R Figlin
Journal:  Oncogene       Date:  1990-09       Impact factor: 9.867

7.  EGFR LI and Ki-67 LI are independent prognostic parameters influencing survivals of surgically treated squamous cell lung cancer patients.

Authors:  J Niemiec; L Kolodziejski; S Dyczek
Journal:  Neoplasma       Date:  2005       Impact factor: 2.575

8.  Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

Authors:  M F Press; M C Pike; V R Chazin; G Hung; J A Udove; M Markowicz; J Danyluk; W Godolphin; M Sliwkowski; R Akita
Journal:  Cancer Res       Date:  1993-10-15       Impact factor: 12.701

Review 9.  The biology of erbB-2/neu/HER-2 and its role in cancer.

Authors:  N E Hynes; D F Stern
Journal:  Biochim Biophys Acta       Date:  1994-12-30

Review 10.  Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  Breast Cancer Res       Date:  2001-11-30       Impact factor: 6.466

View more
  4 in total

1.  Correlation of cell cycle regulatory proteins (p53 and p16(ink)⁴(a)) and bcl-2 oncoprotein with mitotic index and thickness of primary cutaneous malignant melanoma.

Authors:  Miloš Kostov; Zaklina Mijović; Dragan Mihailović; Snežana Cerović; Miroslav Stojanović; Marija Jelić
Journal:  Bosn J Basic Med Sci       Date:  2010-11       Impact factor: 3.363

2.  Lung tumor development in the presence of sphingosine 1-phosphate agonist FTY720.

Authors:  Natália R Salinas; Camila T Lopes; Patrícia V Palma; Celina T Oshima; Valquiria Bueno
Journal:  Pathol Oncol Res       Date:  2009-02-12       Impact factor: 3.201

3.  Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases.

Authors:  A S Berghoff; A Ilhan-Mutlu; A Wöhrer; M Hackl; G Widhalm; J A Hainfellner; K Dieckmann; T Melchardt; B Dome; H Heinzl; P Birner; M Preusser
Journal:  Strahlenther Onkol       Date:  2014-02-28       Impact factor: 3.621

4.  The effects of alternative splicing on miRNA binding sites in bladder cancer.

Authors:  Seonggyun Han; Dongwook Kim; Manu Shivakumar; Young-Ji Lee; Tullika Garg; Jason E Miller; Ju Han Kim; Dokyoon Kim; Younghee Lee
Journal:  PLoS One       Date:  2018-01-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.